
Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap
BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced recent approval for additional European clinical trial sites for the ongoing Phase 3 study of buntanetap for the treatment of Parkinson’s disease (“PD”).
Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap Read More